Hengyi Biopharmaceutical

Hengyi Biopharmaceutical is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative therapies for metabolic, autoimmune, and inflammatory diseases. Founded by former leadership from Jiangsu Hengrui Medicine, the company has established a deep pipeline of late-stage assets, including several candidates in Phase 3 clinical trials. Key programs focus on targets such as URAT1 for gout, PCSK9 for hyperlipidemia, and IL-17A for psoriasis. Hengyi leverages a combination of internal R&D and strategic licensing to advance its portfolio, supported by a strong network of global investors. The company aims to provide high-quality, affordable innovative medicines to patients worldwide, with a primary focus on the Chinese market.